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use, and recipient age are not. Multivariable analysis was
challenging given the correlation among covariates.
However, male donor is signiﬁcantly associated with
improved OS for pts with grade 3-4 aGVHD in all models,
while time pd is not signiﬁcant when adjusting for other
factors.
Conclusions: While OS for pts with grade 3-4 aGVHD has
improved, it continues to impact >13% of pts and has poor
outcomes. The use of a male donor may predict improved OS
for pts with grade 3-4 aGVHD independent of time pd.
Additional study is warranted to validate these ﬁndings and
improve therapies.425
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Risk of acute GVHD varies among different ethnic population.
Thus, we evaluated potential differences in cGVHD mani-
festations in two ethnic distinct cohorts. The study included
a Brazilian cohort diagnosed with cGVHD by 2005 NIH
criteria who were enrolled in a prospective multicenter
longitudinal study at 5 centers in Brazil and compared with
a North American cohort reported by the cGVHD consortium
(Arai S. et al. Blood 2011). Pts. were assessed using stan-
dardized clinical data forms every 3 months (124 visits). Any
elevation of liver function tests was scored as cGVHD. The
Brazilian study cohort included 36 pts. with a median age of
44 (13-64) years and 21 (58%) were male. At study enroll-
ment, 24 (67%) had classic cGVHD, and 12 (33%) pts. had
overlap subtype (with feature of both acute and chronic).
Distribution of organ involvement attributed to cGVHD for
the Brazilian and the North American cohorts at study
enrollment is shown in the Figure. Liver severity scores at
study enrollment was mild in 10 (34%), moderate in 12 (40%)
and severe in 8 (26%) pts. among Brazilian cohort, and it was
mild in 113 (76%), moderated in 36 (24%) and none severe in
the North American cohort. Overall, cGVHD global severity at
study enrollment was calculated from reported data as mild
in 2 (5.5%), moderate in 17 (47%) and severe in 17 (47%) of
Brazilian cohort compared to 32 (10%),175 (59%) and 91(31%)
in the North American cohort, respectively. Similar to North
American cohort, distribution of global severity was similar
in the Brazilian cohort across 22 incident (enrollment < 3
months of cGVHD diagnosis) and 14 prevalent cases
(enrollment 3 or 6 months after cGVHD diagnosis) and,
between pts. with classic and overlap cGVHD. Prevalence of
organs involvement at study enrollment was signiﬁcant
different between the two population. Compared to theNorth American cohort, the Brazilian cohort had higher rates
of liver involvement (83% vs. 50%; p < .001) and lower rate of
lung (8% vs. 50%; p < .001), respectively. The cause for the
high incidence and severity scores in the liver among the
Brazilian cohort is unknown, but we speculated potential
contributors. For instance, 100% of Brazilian cohort was CMV
positive and pre-emptive treatment for CMV reactivation is
not used after day 100 posttransplant, thus reactivation of
CMV may have contributed to the elevation of liver function
tests. Moreover, it is not standard practice in Brazil to add
ursodiol to treat elevation of liver tests attributed to GVHD,
thus allowing for further potential increase in liver severity
score. The lower rates of lung in the Brazilian cohort may
reﬂect non-standardization of pulmonary function test in
Brazil. In conclusion, prevalence of organ manifestations in
cGVHD varied between the two ethnic distinct cohort
studied. Attention should be taken into consideration when
evaluating prognosis and outcomes in cGVHD in different
ethnic population.
Figure 1.426
Clinical Features of Acute Cutaneous Graft-Versus-Host
Disease Following Allogeneic Hematopoietic Stem Cell
Transplantation
Daniel Bach 1, Elizabeth Damstetter 1, Dennis West 2,
Jayesh Mehta 3, Jonathan Cotliar 4. 1 Northwestern University
Feinberg School of Medicine, Chicago, IL; 2 Northwestern
University Feinberg School of Medicine, IL; 3 Northwestern
Memorial Hospital, Chicago, IL; 4 Dermatology, Northwestern
University Feinberg School of Medicine, Chicago, IL
Background: Acute graft-versus-host disease (aGVHD) is
a frequent complication of allogeneic hematopoietic stem
cell transplantation (HSCT). Although the presence of a skin
eruption is a cornerstone in the diagnosis of aGVHD
according to the Glucksberg criteria and the 2005 NIH
Consensus Conference, speciﬁc cutaneous features such as
morphology and anatomic distribution have not been
studied in a systematic manner. Subsequently, the relative
incidences of speciﬁc skin lesions remain unclear and
contribute to the ongoing challenge of delineating aGVHD
from other commonly seen skin eruptions early after HSCT.
Methods: A retrospective review of all patients receiving an
allogeneic HSCT from 2010 to 2011 at Northwestern Memo-
rial Hospital identiﬁed those individuals with cutaneous
aGVHD. Each case of aGVHD was conﬁrmed by both skin
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Cutaneous features with respect to lesion morphology,
location, and time of onset following transplantation were
collected for each patient and further stratiﬁed by aGVHD
clinical grade.
Results: For all cutaneous aGVHD patients (n¼37), the onset
of rash was on average, day +45 (range +4 to +153). The most
common skin lesion morphology was morbilliform (55%)
followed by patchy erythema (38%). Follicular accentuation
was seen in 29% of rashes. The cutaneous eruptions most
commonly occurred on the trunk (69%), arms/legs (67%), face
(62%), ears (38%) and palms (38%).
Comparing grade I and II skin aGVHD patients, grade I
patients (n¼11) had more patchy erythema (73% vs 23%,P ¼
.008), purpuric/violaceous lesions (55% vs 15%,P ¼ .038) or
a reticular pattern (36% vs 0%,P ¼ .005) than grade II patients
(n¼26). Grade II aGVHD patients were found to have cuta-
neous eruptions located more often on the trunk (85% vs
36%,P ¼ .006) and arms/legs (77% vs 36%,P ¼ .028) when
compared to grade I aGVHD patients. Comparison to grade III
(n¼3) and IV (n¼2) aGVHD patients was not performed given
the paucity of cases.
Conclusion: We proﬁled the salient cutaneous features
associated with aGVHD and their relative incidences based
on clinical grade, skin lesion morphology and anatomic site
of involvement. Application of this analysis will allow for
improvements in the diagnosis of aGVHD and differentiation
from other clinical mimickers. Differences in lesional
morphology and location may differentiate grade I and II
cutaneous aGVHD and serve to guide appropriate treatment.427
Survival Improvements Following Omega-3
Polyunsaturated Fatty Acid Dietary Enrichment,
Acetylsalicylic Acid, and Aspirin-Triggered Lipoxin
Administration in a Lethal Mouse Model of Acute Graft-
Versus-Host Disease
Geoff Cuvelier 1, Yuri Lissitsyn 2, Khuong Le 3,
Mohammed Moghadasian 3, Cindy Ellison 2,4. 1 Pediatric
Oncology-Hematology, CancerCare Manitoba, Winnipeg, MB,
Canada; 2 Department of Pathology, University of Manitoba,
Winnipeg, MB, Canada; 3Human Nutritional Sciences,
University of Manitoba; 4 CancerCare Manitoba, Winnipeg, MB,
Canada
Background: Lipoxins (derived from arachidonic acid) and
the resolvins and protectins (derived from u3-poly-
unsaturated fatty acids (PUFAs)) are endogenously produced
lipid mediators with potent anti-inﬂammatory and tissue
healing properties. Acetylsalicylic acid (ASA, aspirin) results
in the synthesis of aspirin-triggered lipoxins, isomers for
these lipid mediators with identical anti-inﬂammatory
actions. In part, these lipid mediators act through down-
regulation of Th1 cytokines known to be important in aGVHD
pathogenesis. The C56BL/6/(C57BL/6 x DBA/2)F1-hybrid is
a major histocompatibility mismatched mouse model of
lethal aGVHD (similar to a non T-cell depleted HLA hap-
loidentical BMT without GVHD prophylaxis) that allows
isolation of the aGVHD effect. We wanted to test whether
these novel lipid mediators could attenuate aGVHD in this
highly inﬂammatory allogeneic transplant mouse model.
Methods: Mice were transplanted according to standard
protocols. Four diets were created, including a control diet
containing 2% u6-PUFAs; and three experimental diets,
enriched for (1) 2%u3-PUFAs (2) 2%u6-PUFAs plus ASA (0.02
mg/g of feed) (3) 2%u3-PUFAs plus ASA. Micewere randomly
fed one diet (n¼10-12 per group) for 8-weeks beforetransplant and the same diet after transplant. A separate
experiment conﬁrmed that feeding the different diets for 8-
weeks before transplant resulted in differential tissue (liver)
stores of u6- and u3-PUFAs. A ﬁfth group (n¼10) was fed the
control diet but injected with the aspirin-triggered lipoxin
15-epi-LxA4 IV on day 0 and IP on day 7 (200 mcg/kg/dose).
The primary outcome was days before the onset of aGVHD-
associated morbidity (humane end point) post-transplant.
Results: Control GVH mice met the humane end-point for
euthanasia as result of aGVHD at a median of 14 days post-
transplant (range: 9-16 days). Kaplan-Meier survival curves
showed modest but statistically signiﬁcant improvements in
survival for mice fed a diet enriched for u3-PUFAs plus ASA
(P¼ .0117) andmice receiving the aspirin-triggered lipoxin (P
¼ .034) compared to the control group. Survival improve-
ments and the onset of lethal aGVHD were delayed by
a matter of days for the mice receiving the interventions.
Conclusion: We provide proof-of-principle that dietary u3-
PUFAs, aspirin, and aspirin-triggered lipoxinsmay offer novel
ways to counteract aGVHD. Our interventions approximate
acceptable human dietary intake for u3-PUFAs and taking
a baby-aspirin once per day. Further experiments using
different aGVHD mouse models are planned.428
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CGVHD develops in more than 50% of survivors of allogeneic
stem cell transplantation and is responsible for mortality in
one third of patients. Long term immunosuppressive therapy
with steroids is the standard treatment. ECP has shown
activity in acute and cGVHD and is successful in about 50% of
the patients after 3 e 6 months of therapy. We studied the
cytokine proﬁles in 6 patients with cGVHD undergoing ECP. A
comprehensive assessment of organ system involvement
using NIH Consensus response assessment tools was done at
study entry and at six months. Patients underwent ECP
treatments twice on two consecutive days every two weeks
for 3 to 6 months. All patients underwent baseline, two-
months, four months and six-month assessments. 10 ml of
leukopheresed blood was obtained from the ECP machine
prior to the initiation of ECP at baseline, and at 2, 4 and 6
months post treatment to assess peripheral blood B and T
cells and the cytokine analysis. CD4+ T cells were puriﬁed
from PBMCs and stimulated with anti-CD3 and anti-CD28 for
ﬁve days. Tissue culture supernatants were collected and
analyzed for the production of 42 cytokines using Luminex
technology. Three patients responded to treatment with ECP
and three did not and later received other therapies. We have
previously reported that responding patients had higher
CD4+CD25+FoxP3+ cells. Of the cytokines analyzed, soluble
CD25 and TNFbwere secreted at signiﬁcantly higher levels in
responding patients prior to ECP initiating therapy (Figure).
In responders, sCD25 and TNFb levels remained high
